A spray containing extracts of oat plantlets and Uncaria tomentosa relieves pain associated with chronic inflammatory skin diseases and dermatological procedures

Background Inflammation from skin conditions such as psoriasis, eczema‐like atopic dermatitis (AD) and hand eczema (HE) and following dermatological procedures (post‐acts) can result in intense itching and cutaneous pain. Dermo‐cosmetics containing plant extracts have been shown to reduce or allevia...

Full description

Saved in:
Bibliographic Details
Published inJournal of the European Academy of Dermatology and Venereology Vol. 34; no. S2; pp. 3 - 11
Main Authors Reich, A., Lopez Estebaranz, J.L., Bahadoran, P., Guillot, P., Carballido, F., Saint Aroman, M.
Format Journal Article
LanguageEnglish
Published England 01.06.2020
Subjects
Online AccessGet full text
ISSN0926-9959
1468-3083
1468-3083
DOI10.1111/jdv.16428

Cover

Loading…
More Information
Summary:Background Inflammation from skin conditions such as psoriasis, eczema‐like atopic dermatitis (AD) and hand eczema (HE) and following dermatological procedures (post‐acts) can result in intense itching and cutaneous pain. Dermo‐cosmetics containing plant extracts have been shown to reduce or alleviate these symptoms. Objectives Assessment of the tolerability and efficacy of a spray containing Rhealba\xAE Oat plantlets and Uncaria tomentosa extracts in adults and children with inflammatory skin diseases and after dermatological procedures. Methods Data from five open label studies were analysed (Study 1: adults with AD; Study 2: children with AD; Study 3: adults with psoriasis; Study 4: adults with HE; Study 5: adults who had undergone a dermatological procedure: laser, intense pulsed light, glycolic acid peeling, photodynamic therapy or cryotherapy procedure). In all studies, subjects could use the test product up to six times per day for symptom relief. Physical and functional signs of inflammation, treatment‐emergent adverse events (TEAEs), soothing effect, changes in quality of life, cutaneous pain and cosmetic acceptability were compared pre‐ and postapplication. Results A total of 176 subjects were enrolled across the five studies. Overall, investigators judged the dermatological tolerance of the test product containing Rhealba\xAE Oat plantlets extract and Uncaria tomentosa as good to excellent. All studies showed significant improvements in physical signs, reduction in itching and feeling of pain (P < 0.05). The soothing effect was evident after the first application. TEAEs were mostly mild, transient and occurred within the first few days of treatment. The majority of subjects reported improved QoL across the studies. Conclusions The dermo‐cosmetic spray containing Rhealba\xAE Oat plantlets extract and U. tomentosa was well tolerated and efficacious in providing relief of symptoms associated with cutaneous pain from inflammatory skin diseases and following dermatological procedures; however, further studies are needed to rule out alternative explanations of symptom reduction such as natural history and response biases.
Bibliography:AR has been a consultant or speaker for AbbVie, Bioderma, Celgene, Chema Elektromet, Eli Lilly, Galderma, Janssen, Leo Pharma, Medac, Menlo Therapeutics, Novartis, Pierre‐Fabre, Sandoz and Trevi; and a principal Investigator or sub‐investigator in clinical trials sponsored by AbbVie, Drug Delivery Solutions Ltd, Galderma, Genentech, Janssen, Kymab Limited, Leo Pharma, Menlo Therapeutics, MetrioPharm, MSD, Novartis, Pfizer and Trev. JLE has been a consultant or speaker for Abbvie, Novartis, Leo, Galderma, Lilly, Janssen and Almirall. PB has received honoraria as a speaker from Pierre Fabre Dermo‐Cosmétique and has been reimbursed by Pierre Fabre Dermo‐Cosmétique for international conference attendance. FC and MSA work within the Pierre Fabre Dermo‐Cosmétique company, in the A‐DERMA brand. PG declares no COIs.
Conflicts of interest
Funding sources
This study was funded by Pierre Fabre Dermo‐Cosmétique.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0926-9959
1468-3083
1468-3083
DOI:10.1111/jdv.16428